October 16, 2014
From left: David Karp, M.D., Ph.D., Sue Manzi, M.D., Martin Hodge, Ph.D., and Robert Carter, M.D., presented at the September 9, 2014, Capitol Hill briefing on the AMP.
From left: David Karp, M.D., Ph.D., Sue Manzi, M.D., Martin Hodge, Ph.D., and Robert Carter, M.D., presented at the September 9, 2014, Capitol Hill briefing on the AMP.

On September 9, 2014, NIAMS Deputy Director Robert Carter, M.D., participated in a Congressional briefing devoted to the Accelerating Medicines Partnership (AMP). The briefing was sponsored by the Lupus Foundation of America (LFA) and the Rheumatology Research Foundation (RRF).

Rep. Jim Moran (D-VA), a Co-Chair of the Congressional Lupus Caucus, attended and gave brief opening remarks. Sue Manzi, M.D., representing the LFA, moderated the session. Dr. Carter provided a broad overview of the AMP and more detail on the AMP Rheumatoid Arthritis and Lupus program. Martin Hodge, Ph.D., from Pfizer, discussed the opportunities to develop better biomarkers and design better clinical trials that will be made possible by AMP. David Karp, M.D., Ph.D., representing the RRF, highlighted the need for additional support to develop new treatments for lupus. A Q&A session followed the presentations. Approximately 80 people attended the event, including 20 Hill staff representing appropriations and authorizing committees, as well as personal offices.

Last Reviewed: